Study: NCT06354088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg
Description: All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg
Description: All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg
Description: All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg
Description: All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [1-13C] sodium acetate
Description: All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [1-13C] sodium acetate
Description: All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [1-13C] sodium acetate
Description: All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [1-13C] sodium acetate
Description: All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé BOOST Plus
Description: All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé BOOST Plus
Description: All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé BOOST Plus
Description: All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé BOOST Plus
Description: All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)